Exelixis (EXEL) Net Income Growth (3y) (2013 - 2026)

Exelixis (EXEL) Net Income Growth (3y) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (3y) (Qtr)
1 Alterity Therapeutics 762,369.55 Bn 762,369.51 Bn - -
2 Belite Bio 55,096.00 Bn 55,096.00 Bn - 84.25%
3 Quantum Biopharma 17,755.80 Bn 17,755.79 Bn - 32.96%
4 Legend Biotech 3,486.00 Bn 3,485.71 Bn 242.10 Mn 30.59%
5 Akari Therapeutics 1,737.42 Bn 1,737.41 Bn - -46.86%
6 Evaxion A 1,551.28 Bn 1,551.26 Bn - 19.97%
7 Psyence Biomedical 227.32 Bn 227.31 Bn - -
8 Vertex Pharmaceuticals 110.84 Bn 103.59 Bn 2.59 Bn 13.80%
9 Abivax 91.71 Bn 91.71 Bn - -
10 Exelixis 13.61 Bn 12.83 Bn 590.86 Mn 73.89%

Historic Data

Download Data
DateValue
Apr 3, 2026 73.89%
Jan 2, 2026 116.19%
Oct 3, 2025 38.28%
Jul 4, 2025 37.78%
Apr 4, 2025 32.53%
Jan 3, 2025 13.69%
Sep 27, 2024 45.62%
Jun 28, 2024 33.01%
Mar 29, 2024 185.65%
Dec 29, 2023 37.66%
Sep 29, 2023 26.67%
Jun 30, 2023 6.70%
Mar 31, 2023 -6.27%
Dec 30, 2022 -33.71%
Sep 30, 2022 -9.09%
Jul 1, 2022 -3.66%
Apr 1, 2022 -3.27%
Dec 31, 2021 -35.83%
Oct 1, 2021 -32.93%
Jul 2, 2021 3.17%